MedTrace Logo

Identification of Proteostasis-related Biomarkers in Alzheimer´s Dementia

NCT02686554 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2022-03-02

No results posted yet for this study

Summary

At the time of biomarker-substantiated diagnosis for a given AD patient it remains unclear to what extent the disease will devastate cognitive abilities within the next years. This is not only unsatisfying for the patient and the attending physician but also a major problem in the context of clinical trials that aim to establish new therapeutic agents. In clinical trials it is critically important to foresee as precisely as possible the course of the disease. The overall aim of the subproject is to identify a panel of CSF biomarkers to further improve specificity of diagnosis ("disease markers"), to measure disease activity and to predict AD progression ("stage and progression markers").

Conditions

  • Alzheimer Disease

Interventions

OTHER

Neuropsychological assessment

The patients perform tests to assess their cognitive abilities

Sponsors & Collaborators

  • Charite University, Berlin, Germany

    lead OTHER

Principal Investigators

  • Oliver Peters, MD · Charité University Medicine, Psychiatry, CBF

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02686554 on ClinicalTrials.gov